BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 18287021)

  • 21. Myelodysplastic Syndromes (MDS) and autoimmune disorders (AD): cause or consequence?
    Braun T; Fenaux P
    Best Pract Res Clin Haematol; 2013 Dec; 26(4):327-36. PubMed ID: 24507810
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Changes of natural kill cell in peripheral blood of patients with myelodysplastic syndrome].
    Mi H; Fu R; Wang H; Qu W; Ruan E; Wang X; Wang G; Liu H; Wu Y; Song J; Xing L; Guan J; Li L; Jiang H; Zhang W; Yue L; Shao Z
    Zhonghua Yi Xue Za Zhi; 2014 Mar; 94(10):737-41. PubMed ID: 24844955
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Role of interleukin-15 in the development of human CD56+ natural killer cells from CD34+ hematopoietic progenitor cells.
    Mrózek E; Anderson P; Caligiuri MA
    Blood; 1996 Apr; 87(7):2632-40. PubMed ID: 8639878
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Real Life Data on Efficacy and Safety of Azacitidine Therapy for Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia.
    Helbig G; Chromik K; Woźniczka K; Kopińska AJ; Boral K; Dworaczek M; Koclęga A; Armatys A; Panz-Klapuch M; Markiewicz M
    Pathol Oncol Res; 2019 Jul; 25(3):1175-1180. PubMed ID: 30613922
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Proliferation and apoptosis in acute and chronic leukemias and myelodysplastic syndrome.
    Lin CW; Manshouri T; Jilani I; Neuberg D; Patel K; Kantarjian H; Andreeff M; Estrov Z; Beran M; Keating M; Estey E; Albitar M
    Leuk Res; 2002 Jun; 26(6):551-9. PubMed ID: 12007503
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Autoimmune disease in CMML-the chicken or the egg?
    Ambinder AJ; Miller J; DeZern AE
    Best Pract Res Clin Haematol; 2020 Jun; 33(2):101136. PubMed ID: 32460986
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expression of TNF receptors and related signaling molecules in the bone marrow from patients with myelodysplastic syndromes.
    Sawanobori M; Yamaguchi S; Hasegawa M; Inoue M; Suzuki K; Kamiyama R; Hirokawa K; Kitagawa M
    Leuk Res; 2003 Jul; 27(7):583-91. PubMed ID: 12681357
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Systemic inflammatory and autoimmune manifestations associated with myelodysplastic syndromes and chronic myelomonocytic leukaemia: a French multicentre retrospective study.
    Mekinian A; Grignano E; Braun T; Decaux O; Liozon E; Costedoat-Chalumeau N; Kahn JE; Hamidou M; Park S; Puéchal X; Toussirot E; Falgarone G; Launay D; Morel N; Trouiller S; Mathian A; Gombert B; Schoindre Y; Lioger B; De Wazieres B; Amoura Z; Buchdaul AL; Georgin-Lavialle S; Dion J; Madaule S; Raffray L; Cathebras P; Piette JC; Rose C; Ziza JM; Lortholary O; Montestruc F; Omouri M; Denis G; Rossignol J; Nimubona S; Adès L; Gardin C; Fenaux P; Fain O
    Rheumatology (Oxford); 2016 Feb; 55(2):291-300. PubMed ID: 26350487
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fas/Apo-1 (CD95) expression and apoptosis in patients with myelodysplastic syndromes.
    Bouscary D; De Vos J; Guesnu M; Jondeau K; Viguier F; Melle J; Picard F; Dreyfus F; Fontenay-Roupie M
    Leukemia; 1997 Jun; 11(6):839-45. PubMed ID: 9177438
    [TBL] [Abstract][Full Text] [Related]  

  • 30. NOX2-dependent immunosuppression in chronic myelomonocytic leukemia.
    Aurelius J; Hallner A; Werlenius O; Riise R; Möllgård L; Brune M; Hansson M; Martner A; Thorén FB; Hellstrand K
    J Leukoc Biol; 2017 Aug; 102(2):459-466. PubMed ID: 28292946
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro effects of IL-2 on NK-activity, clonogenic potential, blast cell proliferation and cytokine release of MDS bone marrow patients.
    Cortelezzi A; Sarina B; Cattaneo C; Pomati M; Silvestris I; Soligo D; Calori R; Di Stefano M; Hu C; Monza M; Radelli L; Maiolo AT
    Leukemia; 1996 Jul; 10(7):1181-9. PubMed ID: 8684000
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Monocyte subset analysis accurately distinguishes CMML from MDS and is associated with a favorable MDS prognosis.
    Talati C; Zhang L; Shaheen G; Kuykendall A; Ball M; Zhang Q; Lancet JE; Zuckerman KS; List AF; Komrokji R; Moscinski L; Padron E
    Blood; 2017 Mar; 129(13):1881-1883. PubMed ID: 28159734
    [No Abstract]   [Full Text] [Related]  

  • 33. A systematic modeling study on the pathogenic role of p38 MAPK activation in myelodysplastic syndromes.
    Peng H; Wen J; Zhang L; Li H; Chang CC; Zu Y; Zhou X
    Mol Biosyst; 2012 Apr; 8(4):1366-74. PubMed ID: 22327869
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of interleukin-12 on natural killer cell cytotoxicity and the production of interferon-gamma and tumour necrosis factor-alpha in patients with myelodysplastic syndromes.
    Ogata K; Tamura H; Yokose N; An E; Dan K; Hamaguchi H; Sakamaki H; Onozawa Y; Clark SC; Nomura T
    Br J Haematol; 1995 May; 90(1):15-21. PubMed ID: 7786778
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Deviation of type I and type II T cells and its negative effect on hematopoiesis in myelodysplastic syndrome.
    Wu L; Li X; Chang C; Ying S; He Q; Pu Q
    Int J Lab Hematol; 2008 Oct; 30(5):390-9. PubMed ID: 19046314
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cutting the cord from myelodysplastic syndromes: chronic myelomonocytic leukemia-specific biology and management strategies.
    Padron E; Steensma DP
    Curr Opin Hematol; 2015 Mar; 22(2):163-70. PubMed ID: 25575034
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predictive Model for Infection Risk in Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia Patients Treated With Azacitidine; Azacitidine Infection Risk Model: The Polish Adult Leukemia Group Study.
    Mądry K; Lis K; Biecek P; Młynarczyk M; Rytel J; Górka M; Kacprzyk P; Dutka M; Rodzaj M; Bołkun Ł; Krochmalczyk D; Łątka E; Drozd-Sokołowska J; Waszczuk-Gajda A; Knopińska-Posłuszny W; Kopińska A; Subocz E; Masternak A; Guzicka-Kazimierczak R; Gil L; Machowicz R; Biliński J; Giebel S; Czerw T; Dwilewicz-Trojaczek J
    Clin Lymphoma Myeloma Leuk; 2019 May; 19(5):264-274.e4. PubMed ID: 30898482
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expression of type 1 insulin-like growth factor receptor in marrow nucleated cells in malignant hematological disorders: correlation with apoptosis.
    Qi H; Xiao L; Lingyun W; Ying T; Yi-Zhi L; Shao-Xu Y; Quan P
    Ann Hematol; 2006 Feb; 85(2):95-101. PubMed ID: 16328478
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cytokine expression patterns and mesenchymal stem cell karyotypes from the bone marrow microenvironment of patients with myelodysplastic syndromes.
    Xiong H; Yang XY; Han J; Wang Q; Zou ZL
    Braz J Med Biol Res; 2015 Mar; 48(3):207-13. PubMed ID: 25608238
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Decidual stromal cells promote the differentiation of CD56
    Yang HL; Zhou WJ; Lu H; Lei ST; Ha SY; Lai ZZ; Zheng ZM; Ruan LY; He YY; Li DJ; Li MQ; Shao J
    Am J Reprod Immunol; 2019 Jun; 81(6):e13110. PubMed ID: 30903677
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.